Full-Time

Manager – Regulatory Affairs Operations

Confirmed live in the last 24 hours

Syndax

Syndax

201-500 employees

Develops cancer therapies and conducts clinical trials

Biotechnology
Healthcare

Mid

Remote in USA

Category
Risk & Compliance
Legal & Compliance
Requirements
  • BA/BS in Life Science/Health related degree or equivalent.
  • Minimum of 3 years of Regulatory Affairs/Operations experience in the biotechnology/pharmaceutical industry.
  • Knowledge and understanding of global regulatory regulations and guidelines.
  • Previous experience in the preparation and submission of regulatory documents for IND/IMPD/NDA/MAAs.
  • Experience with investigational products; hematology and oncology experience a plus.
  • Hands-on contributor willing to perform a wide variety of tasks to support business needs.
  • Ability to work in a cross-functional team environment and a flexible team-oriented perspective.
  • Strong attention to detail and the ability to handle multiple tasks.
  • Excellent organizational, computer and documentation skills.
  • Strong interpersonal skills and the ability to deal effectively with various team members including medical, scientific and manufacturing staff.
Responsibilities
  • Coordinate and prepare regulatory submissions to health authorities including FDA, EMA and other national authorities to support clinical trials, including original IND/CTA submissions, new protocols, protocol amendments, safety reports, new investigator information, and annual reports.
  • Provide regulatory support to the clinical study teams (review clinical protocols, informed consent forms, Investigator’s Brochures, and site documentation).
  • Coordinate and prepare responses to requests for information from health authorities.
  • Manage the regulatory operations function, to include management of publishing vendors.
  • Coordinate with Regulatory Medical Writing, IT, and other functional areas as needed to accomplish Regulatory Operations objectives.
  • Serve as representative to Regulatory Agencies on technical aspects of eCTD/NeeS filings.
  • Manage customization of INDs/IMPDs, BLAs/MAAs, SPL, and briefing dossiers, provide document formatting support, and organize submissions in a professional, compliant, high-quality, and timely manner.
  • Maintain expert knowledge of regional regulatory publishing requirements and precedents that may affect company filings.
  • Manage the implementation of systems and process improvements to support greater efficiency in regulatory operations.
  • Maintain a world-class regulatory operation system and standards including publishing and archiving.
  • Interface regularly with Regulatory Leads to maintain an overview of upcoming submissions for all products and prioritize between the different projects.

Syndax Pharmaceuticals develops and commercializes therapies specifically for cancer patients, focusing on challenging cases like hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer. The company conducts research and clinical trials to test the safety and effectiveness of its drugs, aiming to bring them to market after receiving regulatory approval. Syndax's main product, Entinostat, is currently in clinical trials combined with Exemestane for treating HR+, HER2- breast cancer. Unlike many competitors, Syndax targets underserved patient populations and relies on strategic partnerships and public offerings to fund its research and development. The goal is to advance cancer treatment by developing new therapies that address the needs of patients with difficult-to-treat cancers.

Company Stage

IPO

Total Funding

$144.3M

Headquarters

Waltham, Massachusetts

Founded

2005

Growth & Insights
Headcount

6 month growth

30%

1 year growth

51%

2 year growth

154%
Simplify Jobs

Simplify's Take

What believers are saying

  • Positive clinical trial results for revumenib in combination therapies suggest strong potential for regulatory approval and market success.
  • The appointment of experienced professionals like Aleksandra Rizo to the board of directors enhances the company's strategic direction and clinical development capabilities.
  • Syndax's inducement grants and stock options for new employees indicate a commitment to attracting and retaining top talent, fostering a culture of innovation.

What critics are saying

  • The highly competitive oncology market requires continuous innovation and successful clinical trials to maintain a competitive edge.
  • Dependence on the success of key products like Entinostat and revumenib means that any setbacks in clinical trials or regulatory approvals could significantly impact the company's growth.

What makes Syndax unique

  • Syndax focuses on developing therapies for difficult-to-treat cancers, particularly HR+, HER2- breast cancer, setting it apart from competitors with broader oncology portfolios.
  • The company's flagship product, Entinostat, and its innovative pipeline, including revumenib and axatilimab, highlight its commitment to targeting specific cancer pathways and patient populations.
  • Syndax's strategic capital raises and public offerings provide robust financial support for its R&D efforts, unlike competitors who may struggle with funding.

Help us improve and share your feedback! Did you find this helpful?